Follow TopoGEN on:
TopoGEN has established Joint collaborative ventures with other biotechnology companies. These relationships create excellent synergy and promote new product ideas and business activity. TopoGEN uses a funding model to advance the goals of the joint venture. Specifcially, the company sponsors research based on validated and published science from other University faculty, other companies or collaborative partners. Please contact us (info@topogen.com) for further information.
TopoGEN has started an inititiative on autoimmunity in a joint venture with the Italian Biotech company, Prius. The collaboration will bring their technologies for diagnosis and disease monitoring of Scleroderma and Multiple Sclerosis to the US. The clinical trials are ongoing in the EU. This partnership promotes a facile transition of the technology into the US market. Autoimmune diseases are chronic problems, especially in women and Western civilization, affecting more than 50 million American citizens. Such chronic diseases represent a major drain on the US health care system and the current projects are designed to address an unmet need of tractable diagnosis and ensuring improved public health. Worldwide market for all 100 autoimmune disorders in man estimated to be more than $250 billion.
Funding Status: Prius is supported by Italian Foundation and State funds from multiple sources.
Joint venture funding comes from NIH (SBIR) Funding.
Methylation (www.methylation.net) represents a joint venture of research diagnostics designed to provide products for developing an understanding of gene silencing in human disease. The company was founded in 2006 and has been profitable since 2008.
Funding Status: This company was started as a spin-off of TopoGEN using our funding model and starting with an SBIR grant.
CareCyte Biologicals is a company that has developed the CARE TestTM (Cancer Recognition Test) for detecting solid tumors. It is a simple blood test that measures the presence of a circulating antibody. Clinical trials conducted in the UK indicate success for diagnosing solid tumors with excellent specificity and selectivity. Ongoing testing in the USA with MD Anderson of Orlando suggest the CARE Test functions well with lung cancer.
Funding Status: This project has been funded by the State of Florida, James and Ester King foundation.
614-451-5810 